Association AH.Heart Disease and Stroke Statistics 2017 At‐a‐Glance.2017.http://www.heartorg/idc/groups/ahamahpublic/@wcm/@sop/@smd/documents/downloadable/ucm_491265pdf. Accessed July 18 2018.
10.1371/journal.ppat.1002212
10.1126/science.272.5262.735
10.1016/j.neuropharm.2015.07.032
10.1164/rccm.201003-0359OC
10.1016/j.kint.2016.08.029
10.1517/13543784.2011.578068
10.1016/0306-3623(85)90001-1
10.1111/j.1399-0039.2011.01780.x
10.1016/j.bbamem.2012.01.002
10.1016/j.immuni.2017.06.020
10.1523/JNEUROSCI.2390-10.2010
Steinberg TH, 1987, Extracellular ATP4‐promotes cation fluxes in the J774 mouse macrophage cell line, J Biol Chem, 262, 3118, 10.1016/S0021-9258(18)61477-2
10.1007/s11302-009-9141-7
10.1590/S0100-879X1998000100004
10.1007/s00210-013-0868-x
10.1007/s11302-011-9215-1
10.1016/j.bbrc.2005.04.087
10.4049/jimmunol.169.8.4108
10.1016/j.bbrc.2008.10.042
10.1016/j.bbrc.2015.10.025
10.1111/j.1476-5381.2011.01303.x
10.1111/j.1469-7793.1999.0723n.x
10.1158/1055-9965.EPI-06-0407
10.1007/s11302-009-9139-1
10.1007/s11302-009-9137-3
10.1152/ajpcell.2000.279.4.C1189
10.1152/ajpcell.2001.280.4.C943
10.1007/s11302-012-9291-x
10.1016/j.neuropharm.2017.09.030
10.1016/j.bbamem.2009.03.006
10.1016/j.bbamem.2010.07.022
10.1111/j.1365-2249.2011.04440.x
Ozaki E, 2015, Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives, J Inflamm Res, 8, 15
10.4049/jimmunol.176.7.3877
10.4049/jimmunol.159.3.1451
10.4049/jimmunol.179.3.1913
10.1146/annurev.immunol.021908.132612
Perregaux D, 1994, Interleukin‐1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity, J Biol Chem, 269, 15195, 10.1016/S0021-9258(17)36591-2
10.1016/j.immuni.2013.05.016
10.1182/blood-2009-10-250803
10.1007/978-981-10-4567-7_14
10.1016/j.cell.2013.02.054
Couillin I, 2013, ATP release and purinergic signaling in NLRP3 inflammasome activation, Front Immunol, 3, 414
10.1016/j.molcel.2012.11.009
10.1016/j.immuni.2016.01.012
10.1007/s00018-016-2274-2
10.1016/S1074-7613(03)00235-8
10.4049/jimmunol.175.11.7611
10.1007/s11302-006-9035-x
10.1016/j.freeradbiomed.2007.02.010
10.1007/s11302-005-6322-x
10.1016/j.cellsig.2011.11.012
10.1016/j.cca.2018.01.032
10.1016/S1074-7613(03)00266-8
10.4049/jimmunol.172.8.4987
10.1016/j.pain.2005.01.002
10.4049/jimmunol.168.12.6436
10.1111/j.1476-5381.2011.01624.x
10.4049/jimmunol.176.5.3115
10.1152/physrev.2001.81.2.767
10.1152/ajpcell.1998.275.3.C766
10.1111/j.1476-5381.1983.tb10514.x
10.1016/S0005-2736(98)00140-0
10.1152/ajpheart.2001.281.1.H334
10.1016/j.yjmcc.2009.08.001
10.1007/s11302-015-9468-1
10.1007/s11302-014-9441-4
10.1007/s00210-009-0403-2
10.1007/s00418-010-0716-8
10.1007/s11302-015-9466-3
10.1007/s11302-013-9388-x
10.1007/s11302-014-9436-1
10.1007/s11302-007-9078-7
Gu M, 2016, Cardioprotective effects of genistin in rat myocardial ischemia‐reperfusion injury studies by regulation of P2X7/NF‐κB pathway, Evid Based Complement Alternat Med, 2016, 5381290
10.1007/s11302-016-9518-3
10.1016/j.neuint.2013.06.003
10.1016/j.brainresbull.2013.05.004
10.1007/s11302-013-9367-2
10.1007/s00380-014-0527-2
10.1016/j.ijcard.2013.12.137
10.1113/expphysiol.2012.068338
10.1371/journal.pone.0037491
10.1161/HYPERTENSIONAHA.108.113282
10.1152/ajprenal.00051.2012
10.1161/CIRCULATIONAHA.110.982777
10.1097/FJC.0000000000000106
10.1371/journal.pone.0107639
10.1007/s40119-018-0104-3
10.1161/CIRCRESAHA.116.309726
10.1080/13543776.2017.1246538
10.1136/annrheumdis-2011-143578
AstraZeneca.AZD9056: Bethesda MD: National Center for Advancing Translational Sciences (NCATS).2011.http://ncats.nih.gov/files/AZD9056.pdf. Accessed January 23 2019.
Eser A, 2015, Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn's disease: a randomized placebo‐controlled, double‐blind, phase IIa study, Inflamm Bowel Dis, 21, 2247
10.1016/j.coph.2017.10.011
Pfizer.CE‐224535/P2X7 Receptor Antagonist: Bethesda MD: National Center for Advancing Translational Sciences (NCATS).2011.https://ncats.nih.gov/files/CE-224535.pdf. Accessed January 23 2019.
10.1111/j.1365-2125.2012.04320.x
GlaxoSmithKline.First time in human study evaluating the safety tolerability pharmacokinetics pharmacodynamics and the effect of food of single assending doses of GSK1482160 2009[updated July 7 2017].https://clinicaltrials.gov/ct2/show/NCT00849134.
KincaidJ CaoY KaubC LonerganD KellyMG.Novel compounds as p2x7 modulators and uses thereof. Google Patents.2010.
LanthalerW.Evotec announces the successful completion of the first Phase I study with EVT 401 an Oral P2X7 receptor antagonist ‐ very good safety profile and confirmed “on target activity”. Germany: Evotec.2009[updated June 29 2009].https://www.evotec.com/en/invest/newsannouncements/p/evotec-announces-the-successful-completion-of-the-first-phase-i-study-with-evt-401-an-oral-p2x7-receptor-antagonistvery-good-safety-profile-and-confirmed-on-target-activity-4447.
10.1016/j.ijcard.2013.03.084
10.1161/CIRCULATIONAHA.117.027400
10.1038/s41598-017-05137-y
10.1152/ajpheart.00305.2011
10.1016/j.bbrc.2013.07.010
10.1016/j.peptides.2016.09.002
10.1016/j.yjmcc.2004.11.005
10.1016/j.ygeno.2003.09.025
10.1007/s11897-014-0231-7
Mertens M, 2009, Anakinra for rheumatoid arthritis, Cochrane Database Syst Rev, CD005121
10.1016/j.amjcard.2013.01.287
10.1371/journal.pone.0033438
